SafeBeat
Contact SalesAI-powered ECG analysis for cardiac therapeutics, from your phone.
By Tanmay Verma, Founder · Last verified 03 Jul 2026
0 views
Added 6d ago
75/100Safe BetIn short
SafeBeat — AI-powered ECG analysis for cardiac therapeutics, from your phone. Best for Electrophysiologists managing atrial fibrillation patients remotely, Cardiologists needing remote medication initiation monitoring, Research teams conducting cardiac clinical trials. Contact Sales pricing.
Is SafeBeat actually worth it?
LiveSee what real users actually say. We scan live discussions, reviews and complaints across the web and hand you an honest verdict — in under a minute.
3 free scans · no card needed · downloadable report
Editorial Verdict
Best for
Electrophysiologists managing atrial fibrillation patients remotelyCardiologists needing remote medication initiation monitoringResearch teams conducting cardiac clinical trialsHealthcare systems aiming to expand remote cardiac care with therapeutic guidance
Not ideal for
Patients without a compatible smartphone or deviceEmergency or acute cardiac event detectionGeneral wellness or non-prescribed monitoringOrganizations needing an FDA-cleared, commercially available solution today
Promising but pre-commercial. SafeBeat's focus on therapeutic guidance over passive monitoring is a real differentiator, but it's not yet for sale. Buyers should watch for FDA clearance and commercial launch before committing.
Compare with: SafeBeat vs Nanox.AI, SafeBeat vs Mindsera, SafeBeat vs Gigasheet
Last verified: July 2026
What independent users actually report about SafeBeat
We ran a structured research pass across product reviews, community discussions, and post-purchase forum threads to surface the patterns vendors won't publish themselves. Below: the recurring strengths, the hidden costs people mention most, and the cohort that consistently regrets adopting this tool.
Recurring strengths
- +Focuses on therapeutic guidance, not just diagnostic monitoring.
- +Explainable AI outputs help clinicians trust and act on recommendations.
- +Works with popular FDA-cleared devices (KardiaMobile, Zio, ICMs).
- +Streamlined alert system aims to reduce false positives and fatigue.
- +Customizable treatment step templates per patient for personalized care.
Recurring frustrations
- −No user reviews or community feedback exists across any platform.
- −Still in investigational phase, not yet commercially available.
- −Pricing unknown—requires contacting sales for any estimate.
- −Dependence on third-party devices may limit patient adoption.
- −No independent validation of accuracy or false positive reduction.
Patterns worth knowing
The tool is promising but lacks community proof of efficacy or usability.
Seen on Reddit, Hacker News, Product Hunt
Third-party device integration is practical but creates dependency.
Seen on Bluesky
Therapeutic guidance focus differentiates from pure monitoring tools.
Seen on Product Hunt, Tech Press
Learning curve
intermediateProductive in ~Days of setup
Hidden costs people mention
- • Cost per patient or per device is unknown until negotiation
- • EHR integration setup may incur additional fees
- • Third-party device costs are not included
Viability Score
75/100
Safe BetHow likely is SafeBeat to still be operational in 12 months? Based on 4 signals — momentum (how recently it shipped), wrapper dependency, revenue model, and web presence.
momentum
55
funding runway
70
website health
90
wrapper dependency
100
Last calculated: July 2026
How we score →Key Features
- AI-based ECG interpretation from single-lead and multi-lead recordings
- Remote therapeutic monitoring for medication initiation and adjustment
- Explainable AI outputs for clinician decision support
- Mobile ECG analysis using third-party FDA-cleared devices (e.g., KardiaMobile, Zio)
- Implantable cardiac monitor remote monitoring integration
- Streamlined alert system to reduce false positives and clinician burden
- Customizable treatment step templates per patient
- Cloud-based dashboard for patient data review
- HIPAA-compliant data storage and transmission
- Integration with electronic health records via API
- Patient-facing mobile app for ECG recording and symptom logging
- Support for mobile cardiac telemetry monitoring
- Proprietary machine learning algorithms for treatment management
About SafeBeat
Contact SalesAdvancedAPI availableMobile · Web · API
SafeBeat Rx is a digital health platform that guides cardiac therapeutics, not just diagnostics. Its specialized AI analyzes ECGs from third-party FDA-cleared devices to power remote therapeutic monitoring (RTM) for medication initiation and adjustment. Designed by clinicians for clinicians, the platform streamlines patient data review and offers explainable AI outputs to reduce alert fatigue. Currently under development and limited to investigational use, SafeBeat targets electrophysiologists and cardiologists managing atrial fibrillation and other arrhythmias. Backed by Y Combinator and NIH grants, it aims to expand access to advanced cardiac care. Unlike passive monitoring tools, SafeBeat provides actionable treatment recommendations based on real-time ECG data.
Behind the Verdict
SafeBeat's pitch is compelling: go beyond monitoring to actually guide treatment. For electrophysiologists drowning in alerts, an AI that filters and suggests medication adjustments could be a lifeline. The team has strong credentials and YC backing. But the platform is still investigational. If you're a healthcare system piloting remote care, SafeBeat might be worth a trial. However, for immediate deployment, look at cleared RPM platforms like Biofourmis or Current Health. Pricing is unlisted, and without FDA clearance, we can't recommend clinical use yet. Real-world caveat: the platform requires compatible third-party devices, which adds procurement complexity.
Researching SafeBeat? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Use Cases
- Remotely monitor and adjust anticoagulation therapy for AFib patients using mobile ECG recordings.
- Reduce hospital readmissions by identifying arrhythmias early through daily mobile cardiac telemetry.
- Enable drug initiation for rate/rhythm control in outpatients with continuous ICM monitoring.
- Provide electrophysiologists with AI-synthesized reports summarizing actionable arrhythmia events.
- Support clinical trials by collecting standardized ECG data with built-in AI analysis.
Limitations
- SafeBeat is currently under development and not yet for sale.
- It is limited by U.S. law to investigational use only.
- No pricing or public API documentation is available.
- Features and integrations may change as the product evolves.
Integrations
KardiaMobileZioReveal LINQConfirm Rx
Resources & Guides
Frequently Asked Questions
Tools that pair well with SafeBeat
Common stack mates teams adopt alongside SafeBeat, with the specific reason each pairing earns its keep.
Featured Head-to-Head Comparisons
Alternatives to SafeBeat
View allUsed SafeBeat? Help shape our editorial sentiment research.